1 Report Business Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
        1.2.2 Asset Purchase
        1.2.3 Collaborative R&D
        1.2.4 Joint Venture
        1.2.5 Licensing
        1.2.6 Other
    1.3 Market by Application
        1.3.1 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
        1.3.2 Pharmaceutical Industry
        1.3.3 Biotechnology
        1.3.4 Medical Care
        1.3.5 Education and Research
        1.3.6 Other
    1.4 Study Objectives
    1.5 Years Considered
2 Global Growth Trends
    2.1 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Perspective (2017-2028)
    2.2 Cancer Monoclonal Antibody Partnering Terms and Agreements Growth Trends by Region
        2.2.1 Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Region: 2017 VS 2021 VS 2028
        2.2.2 Cancer Monoclonal Antibody Partnering Terms and Agreements Historic Market Size by Region (2017-2022)
        2.2.3 Cancer Monoclonal Antibody Partnering Terms and Agreements Forecasted Market Size by Region (2023-2028)
    2.3 Cancer Monoclonal Antibody Partnering Terms and Agreements Market Dynamics
        2.3.1 Cancer Monoclonal Antibody Partnering Terms and Agreements Industry Trends
        2.3.2 Cancer Monoclonal Antibody Partnering Terms and Agreements Market Drivers
        2.3.3 Cancer Monoclonal Antibody Partnering Terms and Agreements Market Challenges
        2.3.4 Cancer Monoclonal Antibody Partnering Terms and Agreements Market Restraints
3 Competition Landscape by Key Players
    3.1 Global Top Cancer Monoclonal Antibody Partnering Terms and Agreements Players by Revenue
        3.1.1 Global Top Cancer Monoclonal Antibody Partnering Terms and Agreements Players by Revenue (2017-2022)
        3.1.2 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Share by Players (2017-2022)
    3.2 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    3.3 Players Covered: Ranking by Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue
    3.4 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Concentration Ratio
        3.4.1 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue in 2021
    3.5 Cancer Monoclonal Antibody Partnering Terms and Agreements Key Players Head office and Area Served
    3.6 Key Players Cancer Monoclonal Antibody Partnering Terms and Agreements Product Solution and Service
    3.7 Date of Enter into Cancer Monoclonal Antibody Partnering Terms and Agreements Market
    3.8 Mergers & Acquisitions, Expansion Plans
4 Cancer Monoclonal Antibody Partnering Terms and Agreements Breakdown Data by Type
    4.1 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Historic Market Size by Type (2017-2022)
    4.2 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Forecasted Market Size by Type (2023-2028)
5 Cancer Monoclonal Antibody Partnering Terms and Agreements Breakdown Data by Application
    5.1 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Historic Market Size by Application (2017-2022)
    5.2 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Forecasted Market Size by Application (2023-2028)
6 North America
    6.1 North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size (2017-2028)
    6.2 North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type
        6.2.1 North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2017-2022)
        6.2.2 North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2023-2028)
        6.2.3 North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Type (2017-2028)
    6.3 North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application
        6.3.1 North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2017-2022)
        6.3.2 North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2023-2028)
        6.3.3 North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Application (2017-2028)
    6.4 North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country
        6.4.1 North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2017-2022)
        6.4.2 North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2023-2028)
        6.4.3 U.S.
        6.4.4 Canada
7 Europe
    7.1 Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size (2017-2028)
    7.2 Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type
        7.2.1 Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2017-2022)
        7.2.2 Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2023-2028)
        7.2.3 Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Type (2017-2028)
    7.3 Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application
        7.3.1 Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2017-2022)
        7.3.2 Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2023-2028)
        7.3.3 Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Application (2017-2028)
    7.4 Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country
        7.4.1 Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2017-2022)
        7.4.2 Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2023-2028)
        7.4.3 Germany
        7.4.4 France
        7.4.5 U.K.
        7.4.6 Italy
        7.4.7 Russia
        7.4.8 Nordic Countries
8 Asia-Pacific
    8.1 Asia-Pacific Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size (2017-2028)
    8.2 Asia-Pacific Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type
        8.2.1 Asia-Pacific Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2017-2022)
        8.2.2 Asia-Pacific Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2023-2028)
        8.2.3 Asia-Pacific Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Type (2017-2028)
    8.3 Asia-Pacific Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application
        8.3.1 Asia-Pacific Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2017-2022)
        8.3.2 Asia-Pacific Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2023-2028)
        8.3.3 Asia-Pacific Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Application (2017-2028)
    8.4 Asia-Pacific Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Region
        8.4.1 Asia-Pacific Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Region (2017-2022)
        8.4.2 Asia-Pacific Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Region (2023-2028)
        8.4.3 China
        8.4.4 Japan
        8.4.5 South Korea
        8.4.6 Southeast Asia
        8.4.7 India
        8.4.8 Australia 
9 Latin America
    9.1 Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size (2017-2028)
    9.2 Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type
        9.2.1 Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2017-2022)
        9.2.2 Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2023-2028)
        9.2.3 Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Type (2017-2028)
    9.3 Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application
        9.3.1 Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2017-2022)
        9.3.2 Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2023-2028)
        9.3.3 Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Application (2017-2028)
    9.4 Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country
        9.4.1 Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2017-2022)
        9.4.2 Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2023-2028)
        9.4.3 Mexico
        9.4.4 Brazil
10 Middle East & Africa
    10.1 Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size (2017-2028)
    10.2 Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type
        10.2.1 Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2017-2022)
        10.2.2 Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2023-2028)
        10.2.3 Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Type (2017-2028)
    10.3 Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application
        10.3.1 Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2017-2022)
        10.3.2 Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2023-2028)
        10.3.3 Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Application (2017-2028)
    10.4 Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country
        10.4.1 Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2017-2022)
        10.4.2 Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2023-2028)
        10.4.3 Turkey
        10.4.4 Saudi Arabia
        10.4.5 UAE
11 Key Players Profiles
    11.1 3SBio
        11.1.1 3SBio Company Details
        11.1.2 3SBio Business Overview
        11.1.3 3SBio Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
        11.1.4 3SBio Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2017-2022)
        11.1.5 3SBio Recent Developments
    11.2 4D Pharma
        11.2.1 4D Pharma Company Details
        11.2.2 4D Pharma Business Overview
        11.2.3 4D Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
        11.2.4 4D Pharma Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2017-2022)
        11.2.5 4D Pharma Recent Developments
    11.3 Abbvie
        11.3.1 Abbvie Company Details
        11.3.2 Abbvie Business Overview
        11.3.3 Abbvie Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
        11.3.4 Abbvie Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2017-2022)
        11.3.5 Abbvie Recent Developments
    11.4 Abzena
        11.4.1 Abzena Company Details
        11.4.2 Abzena Business Overview
        11.4.3 Abzena Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
        11.4.4 Abzena Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2017-2022)
        11.4.5 Abzena Recent Developments
    11.5 Adaptive Biotechnologies
        11.5.1 Adaptive Biotechnologies Company Details
        11.5.2 Adaptive Biotechnologies Business Overview
        11.5.3 Adaptive Biotechnologies Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
        11.5.4 Adaptive Biotechnologies Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2017-2022)
        11.5.5 Adaptive Biotechnologies Recent Developments
    11.6 Aeglea BioTherapeutics
        11.6.1 Aeglea BioTherapeutics Company Details
        11.6.2 Aeglea BioTherapeutics Business Overview
        11.6.3 Aeglea BioTherapeutics Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
        11.6.4 Aeglea BioTherapeutics Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2017-2022)
        11.6.5 Aeglea BioTherapeutics Recent Developments
    11.7 Agenus Bio
        11.7.1 Agenus Bio Company Details
        11.7.2 Agenus Bio Business Overview
        11.7.3 Agenus Bio Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
        11.7.4 Agenus Bio Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2017-2022)
        11.7.5 Agenus Bio Recent Developments
    11.8 Ascension
        11.8.1 Ascension Company Details
        11.8.2 Ascension Business Overview
        11.8.3 Ascension Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
        11.8.4 Ascension Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2017-2022)
        11.8.5 Ascension Recent Developments
    11.9 Ascentage Pharma
        11.9.1 Ascentage Pharma Company Details
        11.9.2 Ascentage Pharma Business Overview
        11.9.3 Ascentage Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
        11.9.4 Ascentage Pharma Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2017-2022)
        11.9.5 Ascentage Pharma Recent Developments
    11.10 Aslan Pharma
        11.10.1 Aslan Pharma Company Details
        11.10.2 Aslan Pharma Business Overview
        11.10.3 Aslan Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
        11.10.4 Aslan Pharma Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2017-2022)
        11.10.5 Aslan Pharma Recent Developments
    11.11 Telix Pharmaceuticals
        11.11.1 Telix Pharmaceuticals Company Details
        11.11.2 Telix Pharmaceuticals Business Overview
        11.11.3 Telix Pharmaceuticals Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
        11.11.4 Telix Pharmaceuticals Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2017-2022)
        11.11.5 Telix Pharmaceuticals Recent Developments
    11.12 Basilea Pharmaceutica
        11.12.1 Basilea Pharmaceutica Company Details
        11.12.2 Basilea Pharmaceutica Business Overview
        11.12.3 Basilea Pharmaceutica Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
        11.12.4 Basilea Pharmaceutica Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2017-2022)
        11.12.5 Basilea Pharmaceutica Recent Developments
    11.13 Bavarian Nordic
        11.13.1 Bavarian Nordic Company Details
        11.13.2 Bavarian Nordic Business Overview
        11.13.3 Bavarian Nordic Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
        11.13.4 Bavarian Nordic Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2017-2022)
        11.13.5 Bavarian Nordic Recent Developments
    11.14 Baxalta
        11.14.1 Baxalta Company Details
        11.14.2 Baxalta Business Overview
        11.14.3 Baxalta Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
        11.14.4 Baxalta Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2017-2022)
        11.14.5 Baxalta Recent Developments
    11.15 Bayer
        11.15.1 Bayer Company Details
        11.15.2 Bayer Business Overview
        11.15.3 Bayer Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
        11.15.4 Bayer Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2017-2022)
        11.15.5 Bayer Recent Developments
    11.16 Cantargia
        11.16.1 Cantargia Company Details
        11.16.2 Cantargia Business Overview
        11.16.3 Cantargia Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
        11.16.4 Cantargia Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2017-2022)
        11.16.5 Cantargia Recent Developments
    11.17 Apollomics
        11.17.1 Apollomics Company Details
        11.17.2 Apollomics Business Overview
        11.17.3 Apollomics Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
        11.17.4 Apollomics Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2017-2022)
        11.17.5 Apollomics Recent Developments
    11.18 Chiome Bioscience
        11.18.1 Chiome Bioscience Company Details
        11.18.2 Chiome Bioscience Business Overview
        11.18.3 Chiome Bioscience Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
        11.18.4 Chiome Bioscience Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2017-2022)
        11.18.5 Chiome Bioscience Recent Developments
    11.19 Clovis Oncology
        11.19.1 Clovis Oncology Company Details
        11.19.2 Clovis Oncology Business Overview
        11.19.3 Clovis Oncology Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction
        11.19.4 Clovis Oncology Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2017-2022)
        11.19.5 Clovis Oncology Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Author Details
    13.3 Disclaimer
                  
              

                

                 
List of Tables
    Table 1. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
    Table 2. Key Players of Asset Purchase
    Table 3. Key Players of Collaborative R&D
    Table 4. Key Players of Joint Venture
    Table 5. Key Players of Licensing
    Table 6. Key Players of Other
    Table 7. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
    Table 8. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
    Table 9. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Region (2017-2022) & (US$ Million)
    Table 10. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Region (2017-2022)
    Table 11. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Forecasted Market Size by Region (2023-2028) & (US$ Million)
    Table 12. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Region (2023-2028)
    Table 13. Cancer Monoclonal Antibody Partnering Terms and Agreements Market Trends
    Table 14. Cancer Monoclonal Antibody Partnering Terms and Agreements Market Drivers
    Table 15. Cancer Monoclonal Antibody Partnering Terms and Agreements Market Challenges
    Table 16. Cancer Monoclonal Antibody Partnering Terms and Agreements Market Restraints
    Table 17. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue by Players (2017-2022) & (US$ Million)
    Table 18. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Share by Players (2017-2022)
    Table 19. Global Top Cancer Monoclonal Antibody Partnering Terms and Agreements by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements as of 2021)
    Table 20. Ranking of Global Top Cancer Monoclonal Antibody Partnering Terms and Agreements Companies by Revenue (US$ Million) in 2021
    Table 21. Global 5 Largest Players Market Share by Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (CR5 and HHI) & (2017-2022)
    Table 22. Key Players Headquarters and Area Served
    Table 23. Key Players Cancer Monoclonal Antibody Partnering Terms and Agreements Product Solution and Service
    Table 24. Date of Enter into Cancer Monoclonal Antibody Partnering Terms and Agreements Market
    Table 25. Mergers & Acquisitions, Expansion Plans
    Table 26. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2017-2022) & (US$ Million)
    Table 27. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Share by Type (2017-2022)
    Table 28. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Forecasted Market Size by Type (2023-2028) & (US$ Million)
    Table 29. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Share by Type (2023-2028)
    Table 30. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2017-2022) & (US$ Million)
    Table 31. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Share by Application (2017-2022)
    Table 32. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Forecasted Market Size by Application (2023-2028) & (US$ Million)
    Table 33. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Share by Application (2023-2028)
    Table 34. North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2017-2022) & (US$ Million)
    Table 35. North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2023-2028) & (US$ Million)
    Table 36. North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2017-2022) & (US$ Million)
    Table 37. North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2023-2028) & (US$ Million)
    Table 38. North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2017-2022) & (US$ Million)
    Table 39. North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2023-2028) & (US$ Million)
    Table 40. Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2017-2022) & (US$ Million)
    Table 41. Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2023-2028) & (US$ Million)
    Table 42. Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2017-2022) & (US$ Million)
    Table 43. Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2023-2028) & (US$ Million)
    Table 44. Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2017-2022) & (US$ Million)
    Table 45. Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2023-2028) & (US$ Million)
    Table 46. Asia Pacific Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2017-2022) & (US$ Million)
    Table 47. Asia Pacific Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2023-2028) & (US$ Million)
    Table 48. Asia Pacific Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2017-2022) & (US$ Million)
    Table 49. Asia Pacific Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2023-2028) & (US$ Million)
    Table 50. Asia Pacific Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Region (2017-2022) & (US$ Million)
    Table 51. Asia Pacific Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Region (2023-2028) & (US$ Million)
    Table 52. Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2017-2022) & (US$ Million)
    Table 53. Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2023-2028) & (US$ Million)
    Table 54. Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2017-2022) & (US$ Million)
    Table 55. Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2023-2028) & (US$ Million)
    Table 56. Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2017-2022) & (US$ Million)
    Table 57. Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2023-2028) & (US$ Million)
    Table 58. Middle East and Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2017-2022) & (US$ Million)
    Table 59. Middle East and Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2023-2028) & (US$ Million)
    Table 60. Middle East and Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2017-2022) & (US$ Million)
    Table 61. Middle East and Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2023-2028) & (US$ Million)
    Table 62. Middle East and Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2017-2022) & (US$ Million)
    Table 63. Middle East and Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2023-2028) & (US$ Million)
    Table 64. 3SBio Company Details
    Table 65. 3SBio Business Overview
    Table 66. 3SBio Cancer Monoclonal Antibody Partnering Terms and Agreements Product
    Table 67. 3SBio Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2017-2022) & (US$ Million)
    Table 68. 3SBio Recent Developments
    Table 69. 4D Pharma Company Details
    Table 70. 4D Pharma Business Overview
    Table 71. 4D Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Product
    Table 72. 4D Pharma Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2017-2022) & (US$ Million)
    Table 73. 4D Pharma Recent Developments
    Table 74. Abbvie Company Details
    Table 75. Abbvie Business Overview
    Table 76. Abbvie Cancer Monoclonal Antibody Partnering Terms and Agreements Product
    Table 77. Abbvie Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2017-2022) & (US$ Million)
    Table 78. Abbvie Recent Developments
    Table 79. Abzena Company Details
    Table 80. Abzena Business Overview
    Table 81. Abzena Cancer Monoclonal Antibody Partnering Terms and Agreements Product
    Table 82. Abzena Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2017-2022) & (US$ Million)
    Table 83. Abzena Recent Developments
    Table 84. Adaptive Biotechnologies Company Details
    Table 85. Adaptive Biotechnologies Business Overview
    Table 86. Adaptive Biotechnologies Cancer Monoclonal Antibody Partnering Terms and Agreements Product
    Table 87. Adaptive Biotechnologies Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2017-2022) & (US$ Million)
    Table 88. Adaptive Biotechnologies Recent Developments
    Table 89. Aeglea BioTherapeutics Company Details
    Table 90. Aeglea BioTherapeutics Business Overview
    Table 91. Aeglea BioTherapeutics Cancer Monoclonal Antibody Partnering Terms and Agreements Product
    Table 92. Aeglea BioTherapeutics Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2017-2022) & (US$ Million)
    Table 93. Aeglea BioTherapeutics Recent Developments
    Table 94. Agenus Bio Company Details
    Table 95. Agenus Bio Business Overview
    Table 96. Agenus Bio Cancer Monoclonal Antibody Partnering Terms and Agreements Product
    Table 97. Agenus Bio Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2017-2022) & (US$ Million)
    Table 98. Agenus Bio Recent Developments
    Table 99. Ascension Company Details
    Table 100. Ascension Business Overview
    Table 101. Ascension Cancer Monoclonal Antibody Partnering Terms and Agreements Product
    Table 102. Ascension Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2017-2022) & (US$ Million)
    Table 103. Ascension Recent Developments
    Table 104. Ascentage Pharma Company Details
    Table 105. Ascentage Pharma Business Overview
    Table 106. Ascentage Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Product
    Table 107. Ascentage Pharma Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2017-2022) & (US$ Million)
    Table 108. Ascentage Pharma Recent Developments
    Table 109. Aslan Pharma Company Details
    Table 110. Aslan Pharma Business Overview
    Table 111. Aslan Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Product
    Table 112. Aslan Pharma Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2017-2022) & (US$ Million)
    Table 113. Aslan Pharma Recent Developments
    Table 114. Telix Pharmaceuticals Company Details
    Table 115. Telix Pharmaceuticals Business Overview
    Table 116. Telix Pharmaceuticals Cancer Monoclonal Antibody Partnering Terms and Agreements Product
    Table 117. Telix Pharmaceuticals Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2017-2022) & (US$ Million)
    Table 118. Telix Pharmaceuticals Recent Developments
    Table 119. Basilea Pharmaceutica Company Details
    Table 120. Basilea Pharmaceutica Business Overview
    Table 121. Basilea Pharmaceutica Cancer Monoclonal Antibody Partnering Terms and Agreements Product
    Table 122. Basilea Pharmaceutica Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2017-2022) & (US$ Million)
    Table 123. Basilea Pharmaceutica Recent Developments
    Table 124. Bavarian Nordic Company Details
    Table 125. Bavarian Nordic Business Overview
    Table 126. Bavarian Nordic Cancer Monoclonal Antibody Partnering Terms and Agreements Product
    Table 127. Bavarian Nordic Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2017-2022) & (US$ Million)
    Table 128. Bavarian Nordic Recent Developments
    Table 129. Baxalta Company Details
    Table 130. Baxalta Business Overview
    Table 131. Baxalta Cancer Monoclonal Antibody Partnering Terms and Agreements Product
    Table 132. Baxalta Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2017-2022) & (US$ Million)
    Table 133. Baxalta Recent Developments
    Table 134. Bayer Company Details
    Table 135. Bayer Business Overview
    Table 136. Bayer Cancer Monoclonal Antibody Partnering Terms and Agreements Product
    Table 137. Bayer Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2017-2022) & (US$ Million)
    Table 138. Bayer Recent Developments
    Table 139. Cantargia Company Details
    Table 140. Cantargia Business Overview
    Table 141. Cantargia Cancer Monoclonal Antibody Partnering Terms and Agreements Product
    Table 142. Cantargia Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2017-2022) & (US$ Million)
    Table 143. Cantargia Recent Developments
    Table 144. Apollomics Company Details
    Table 145. Apollomics Business Overview
    Table 146. Apollomics Cancer Monoclonal Antibody Partnering Terms and Agreements Product
    Table 147. Apollomics Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2017-2022) & (US$ Million)
    Table 148. Apollomics Recent Developments
    Table 149. Chiome Bioscience Company Details
    Table 150. Chiome Bioscience Business Overview
    Table 151. Chiome Bioscience Cancer Monoclonal Antibody Partnering Terms and Agreements Product
    Table 152. Chiome Bioscience Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2017-2022) & (US$ Million)
    Table 153. Chiome Bioscience Recent Developments
    Table 154. Clovis Oncology Company Details
    Table 155. Clovis Oncology Business Overview
    Table 156. Clovis Oncology Cancer Monoclonal Antibody Partnering Terms and Agreements Product
    Table 157. Clovis Oncology Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2017-2022) & (US$ Million)
    Table 158. Clovis Oncology Recent Developments
    Table 159. Research Programs/Design for This Report
    Table 160. Key Data Information from Secondary Sources
    Table 161. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Type: 2021 VS 2028
    Figure 2. Asset Purchase Features
    Figure 3. Collaborative R&D Features
    Figure 4. Joint Venture Features
    Figure 5. Licensing Features
    Figure 6. Other Features
    Figure 7. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Application: 2021 VS 2028
    Figure 8. Pharmaceutical Industry Case Studies
    Figure 9. Biotechnology Case Studies
    Figure 10. Medical Care Case Studies
    Figure 11. Education and Research Case Studies
    Figure 12. Other Case Studies
    Figure 13. Cancer Monoclonal Antibody Partnering Terms and Agreements Report Years Considered
    Figure 14. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size (US$ Million), Year-over-Year: 2017-2028
    Figure 15. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size, (US$ Million), 2017 VS 2021 VS 2028
    Figure 16. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Region: 2021 VS 2028
    Figure 17. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Players in 2021
    Figure 18. Global Top Cancer Monoclonal Antibody Partnering Terms and Agreements Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements as of 2021)
    Figure 19. The Top 10 and 5 Players Market Share by Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue in 2021
    Figure 20. North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY (2017-2028) & (US$ Million)
    Figure 21. North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Market Share by Type (2017-2028)
    Figure 22. North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Market Share by Application (2017-2028)
    Figure 23. North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Share by Country (2017-2028)
    Figure 24. United States Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 25. Canada Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 26. Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY (2017-2028) & (US$ Million)
    Figure 27. Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Market Share by Type (2017-2028)
    Figure 28. Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Market Share by Application (2017-2028)
    Figure 29. Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Share by Country (2017-2028)
    Figure 30. Germany Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 31. France Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 32. U.K. Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 33. Italy Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 34. Russia Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 35. Nordic Countries Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 36. Asia-Pacific Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY (2017-2028) & (US$ Million)
    Figure 37. Asia Pacific Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Market Share by Type (2017-2028)
    Figure 38. Asia Pacific Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Market Share by Application (2017-2028)
    Figure 39. Asia Pacific Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Share by Region (2017-2028)
    Figure 40. China Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 41. Japan Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 42. South Korea Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 43. Southeast Asia Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 44. India Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 45. Australia Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2017-2028) & (US$ Million)
List of Figures
    Figure 46. Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY (2017-2028) & (US$ Million)
    Figure 47. Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Market Share by Type (2017-2028)
    Figure 48. Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Market Share by Application (2017-2028)
    Figure 49. Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Share by Country (2017-2028)
    Figure 50. Mexico Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 51. Brazil Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 52. Middle East & Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY (2017-2028) & (US$ Million)
    Figure 53. Middle East and Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Market Share by Type (2017-2028)
    Figure 54. Middle East and Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Market Share by Application (2017-2028)
    Figure 55. Middle East and Africa Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Share by Country (2017-2028)
    Figure 56. Turkey Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 57. Saudi Arabia Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 58. UAE Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 59. 3SBio Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2017-2022)
    Figure 60. 4D Pharma Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2017-2022)
    Figure 61. Abbvie Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2017-2022)
    Figure 62. Abzena Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2017-2022)
    Figure 63. Adaptive Biotechnologies Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2017-2022)
    Figure 64. Aeglea BioTherapeutics Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2017-2022)
    Figure 65. Agenus Bio Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2017-2022)
    Figure 66. Ascension Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2017-2022)
    Figure 67. Ascentage Pharma Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2017-2022)
    Figure 68. Aslan Pharma Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2017-2022)
    Figure 69. Telix Pharmaceuticals Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2017-2022)
    Figure 70. Basilea Pharmaceutica Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2017-2022)
    Figure 71. Bavarian Nordic Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2017-2022)
    Figure 72. Baxalta Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2017-2022)
    Figure 73. Bayer Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2017-2022)
    Figure 74. Cantargia Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2017-2022)
    Figure 75. Apollomics Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2017-2022)
    Figure 76. Chiome Bioscience Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2017-2022)
    Figure 77. Clovis Oncology Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2017-2022)
    Figure 78. Bottom-up and Top-down Approaches for This Report
    Figure 79. Data Triangulation
    Figure 80. Key Executives Interviewed